sequences revealed that the HSV-2 nucleic acid segment most likely encodes two distinct proteins. The first protein is the HSV-2 protease, which is required for the assembly of the herpes virus capsid. The second protein has been previously designated as ICP35 in HSV-1, and belongs to the family of herpesvirus capsid proteins.
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The recent discovery of the herpes simplex virus type 1 (HSV-1) UL26 gene has generated intense interest. Encoding both a serine protease and its substrate ICP35, UL26 was the first gene in its class to be identified within the herpesvirus family (Liu & Roizman, 1991 a, b, 1992 McGeoch et al., 1988) . Recent insight into the function of this protease has shed new light on the genesis and maturation of herpesvirus particles. Because of its essential role in virus replication, the protease encoded by UL26 has emerged as a new and attractive antiviral target (Gao et al., 1994) . Moreover, treatment strategies aimed at the protease may be broadly applicable to all herpesvirus infections. Amino acid sequence homologies exist among confirmed (HSV-I and cytomegalovirus) and predicted (varicella-zoster virus and Epstein-Barr virus) herpesvirus proteases and their substrates (Baum et al., 1993; Davison et al., 1992; Dilanni et al., 1993; Liu & Roizman, 1992; Preston et aL, 1983; Welch et al., 1991 Welch et al., , 1993 . Also, there is evidence from early work that HSV-2 homologues of HSV-1 nucleocapsid proteins exist (Marsden et al., 1978; Zweig et al., 1979 Zweig et al., , 1980 . However, up to the present time, a homologue of the HSV-1 UL26 gene has not been identified on the HSV-2 genome.
To determine whether a homologue of the HSV-1 UL26 gene is encoded by HSV-2, we obtained the nucleic acid segment encoding the HSV-1 protease gene and utilized it as a probe for detecting homologous sequences *Author for correspondence. Fax + 1 708 938 1021.
The sequence information in this paper has been deposited in GenBank under accession number L37443.
within the HSV-2 genome by Southern blot analysis. HSV-2 DNA was digested with restriction enzymes, fractionated by electrophoresis in agarose gels, and transferred to nitrocellulose. A nick-translated 3~p_ labelled probe of the HSV-1 protease gene was added to the blot and left to hybridize overnight. After extensive washing, the blot was subjected to autoradiography. Several HSV-2 DNA fragments which appeared highly homologous to the HSV-1 UL26 gene were subsequently cloned into pUC 19.
We have determined the nucleotide sequence of HSV-2 UL26 gene within a 2.6 kb nucleic acid segment mapping from approximately 0.33 to 0.35 map units on the viral genome. Sail and BamHI fragments were subcloned into M 13 vectors and single-stranded phage DNAs were used as templates for sequencing. The nucleotide sequence of the HSV-2 strain G UL26 gene is shown in Fig. 1 . The open reading frame extends from the ATG start site at nt + 1 to a TGA termination signal 1908 nucleotides downstream. The 636 codons it contains predict a polypeptide product of 80 000 Da. No apparent TATA homology exists upstream from the start of translation, although the sequence TAAAA at position 74 relative to the ATG start signal may serve as the TATA box. Furthermore, no other ATG codons were found between the putative promoter signal at nt 74 and the ATG codon at nt + 1, suggesting that the ATG codon at nt + 1 is the likely start of translation.
In agreement with Liu & Roizman (1991b) , an endogenous promoter appears to direct expression of the ICP35 capsid protein. The second transcriptional unit is predicted to specify a protein of 329 amino acids and is found in a position nearly identical to the ICP35 promoter of HSV-1. A TATA homology is present at position + 796 and the ATG translational start site for ICP35 is found downstream at +922 relative to the UL26 translational start site. Significant nucleotide sequence homology exists between the coding regions of the HSV-1 and HSV-2 UL26 genes. Sequence analysis demonstrates that an 87% identity exists between the protease domains from nt + 1 to nt +741. However, from nt +742 to +921, which contains the endogenous promoter region of ICP35, there is considerably less sequence homology of only 67%. The spatial arrangements between the ICP35 promoter elements of HSV-1 and HSV-2, on the other hand, remain relatively unchanged. The coding sequence of ICP35, which extends from nt + 922 to the TGA stop codon at + 1908 displays a 74 %0 identity, which is less than that observed between the UL26 protease domains.
The sequence of the first 247 amino acids encoded by the HSV-2 UL26 gene shows 90% identity to the established functional domain of the HSV-1 protease. This high level of homology extends through residue 252, and therefore predicts an autoproteolytic release site between amino acids 247 and 248 which is analogous to that found in HSV-1 (Welch et al., 1991 ; Dilanni et al., 1993) . In contrast to the protease functional domain, only 68 % identity in amino acid sequence exists between the HSV-1 and HSV-2 ICP35 capsid proteins. However, the 15 amino acids flanking the putative C-terminal proteolytic maturation site (610/611) in HSV-2 are identical to the HSV-1 residues. Overall, the full-length proteins encoded by UL26 share 76 % identity (Fig. 2) .
In the present study we have determined the nucleotide sequence of the HSV-2 UL26 gene. Comparisons of the predicted amino acid sequences of HSV-1 and HSV-2 UL26 genes have shown that the protease domains are highly homologous, while the ICP35 capsid proteins are somewhat less homologous. In addition, amino acid sequences at the protease release and capsid maturation sites are identical. This sequence data for the HSV-2 UL26 gene furthers our understanding of the structural relatedness of the herpesvirus proteases. Because the catalytic domains of these essential enzymes appear to be highly conserved, inhibitors with broad spectrum antiviral activity should be actively pursued.
We thank Dan Norbeck and Akhter Molla for the critical reading of this manuscript.
